{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:47:08Z","timestamp":1778629628187,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T00:00:00Z","timestamp":1555891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"the responsibility of Pfizer Japan Inc"},{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Akihiko Uegaki and Haruna Kitamura of Interscience Co., Ltd"},{"name":"Hironori Kikkawa and Kentaro Kaneyasu of Pfizer Japan Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Post-marketing surveillance (PMS) was performed in Japan to obtain information on the safety and efficacy of crizotinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Target patients included almost all patients with anaplastic lymphoma kinase-positive non-small cell lung cancer who were administered crizotinib. The observation period was 52 weeks. In the present study, we focused on the treatment status and safety of crizotinib therapy and analyzed the real-world data obtained by this PMS (ClinicalTrials.gov: NCT01597258).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The safety analysis set included 2028 Japanese patients, and more than half of the patients (56.4%) were nonsmokers. The incidence of adverse drug reactions (ADRs) was 91.6%, and common ADRs (incidence \u226515%) were nausea (32.2%), diarrhea (24.3%), photopsia (18.9%), vomiting (17.5%) and dysgeusia (16.8%). Many patients (623 patients) discontinued treatment of crizotinib because of adverse events within 12 weeks after therapy initiation, which tended to frequently occur in the following cases: (1) elderly, (2) body weight &lt;40 kg, (3) body surface area &lt;1.2 m2 (4) ECOG PS 2\u20134, (5) higher Brinkman index and (6) history of occupational\/environmental exposure such as asbestos\/pneumoconiosis. The proportions of patients remaining on crizotinib therapy were 68.2% for 3 months, 55.2% for 6 months and 36.1% for 12 months, with a median duration of 7.9 months. Multivariate analysis with a Cox proportional hazard model identified 10 statistically significant patient background factors influencing the duration of crizotinib therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No new safety concerns were observed in this PMS study. Our results provide useful information regarding the status of crizotinib therapy in the clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jjco\/hyz049","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T11:10:14Z","timestamp":1554808214000},"page":"676-686","source":"Crossref","is-referenced-by-count":14,"title":["Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings"],"prefix":"10.1093","volume":"49","author":[{"given":"Naomi","family":"Ueno","sequence":"first","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Banno","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoko","family":"Tamura","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuko","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hashigaki","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Ohki","sequence":"additional","affiliation":[{"name":"Pfizer Japan Inc, 3-22-7 Yoyogi, Shibuya-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinobu","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gemma","sequence":"additional","affiliation":[{"name":"Graduate School of Medicine, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,22]]},"reference":[{"key":"2019070310230102700_hyz049C1","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF\u22122341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2019070310230102700_hyz049C2","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"2019070310230102700_hyz049C3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2019070310230102700_hyz049C4","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"2019070310230102700_hyz049C5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1097\/JTO.0000000000000318","article-title":"Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer","volume":"9","author":"Blackhall","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2019070310230102700_hyz049C6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"2019070310230102700_hyz049C7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib with chemotherapy: results from PROFILE 1014","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"2019070310230102700_hyz049C8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0000000000000577","article-title":"Crizotinib associated with ground-glass opacity predominant pattern interstitial lung disease: a retrospective observational cohort study with a systematic literature review","volume":"10","author":"Cr\u00e9quit","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2019070310230102700_hyz049C9","doi-asserted-by":"crossref","first-page":"9480","DOI":"10.18632\/oncotarget.23840","article-title":"Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2019070310230102700_hyz049C10","doi-asserted-by":"crossref","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","article-title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer","volume":"2","author":"Blackhall","year":"2017","journal-title":"ESMO Open"},{"key":"2019070310230102700_hyz049C11","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.3747\/co.25.3723","article-title":"Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib","volume":"25","author":"Davis","year":"2018","journal-title":"Curr Oncol"},{"key":"2019070310230102700_hyz049C12","doi-asserted-by":"crossref","first-page":"e70839","DOI":"10.1371\/journal.pone.0070839","article-title":"Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS One"},{"key":"2019070310230102700_hyz049C13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cllc.2014.09.008","article-title":"Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"Clin Lung Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyz049\/28495044\/hyz049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/49\/7\/676\/28900339\/hyz049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T21:19:36Z","timestamp":1607203176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/49\/7\/676\/5476038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,22]]},"references-count":13,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,4,22]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyz049","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,4,22]]}}}